Nuvalent Inc (NUVL)
86.88
-3.30
(-3.66%)
USD |
NASDAQ |
Nov 15, 16:00
86.84
-0.04
(-0.05%)
After-Hours: 20:00
Nuvalent Cash from Financing (Quarterly): 550.27M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 550.27M |
| June 30, 2024 | 4.137M |
| March 31, 2024 | 5.986M |
| December 31, 2023 | 333.42M |
| September 30, 2023 | 2.143M |
| June 30, 2023 | 1.298M |
| March 31, 2023 | -0.017M |
| December 31, 2022 | 248.67M |
| September 30, 2022 | 1.006M |
| June 30, 2022 | 0.005M |
| Date | Value |
|---|---|
| March 31, 2022 | -0.768M |
| December 31, 2021 | -0.944M |
| September 30, 2021 | 174.93M |
| June 30, 2021 | 134.23M |
| March 31, 2021 | 10.00M |
| December 31, 2020 | 0.015M |
| September 30, 2020 | 10.00M |
| June 30, 2020 | -0.25M |
| March 31, 2020 | 12.50M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.944M
Minimum
Dec 2021
550.27M
Maximum
Sep 2024
78.24M
Average
4.137M
Median
Jun 2024
Cash from Financing (Quarterly) Benchmarks
| Viking Therapeutics Inc | 2.522M |
| Bristol-Myers Squibb Co | -3.852B |
| Replimune Group Inc | -0.039M |
| Moderna Inc | 11.00M |
| NovaBay Pharmaceuticals Inc | 2.089M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -45.82M |
| Cash from Investing (Quarterly) | -212.91M |
| Free Cash Flow | -153.27M |
| Free Cash Flow Per Share (Quarterly) | -0.6976 |
| Free Cash Flow Yield | -2.75% |